SCHEMBL22029484

SCHEMBL22029484

O=C(O)c1nc2ccccc2n1CC1CC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 5/20 0.51
KDM4E B2RXH2 4/20 0.49
ALDH1A1 P00352 3/20 0.49
HSD17B10 Q99714 3/20 0.49
TP53 P04637 1/20 0.49
TSHR P16473 1/20 0.49
HTT P42858 1/20 0.49
PTGER4 P35408 4/20 0.48
PRKACA P17612 1/20 0.48
RPS6KB1 P23443 1/20 0.48
GSK3B P49841 1/20 0.48
ROCK1 Q13464 1/20 0.48
POLB P06746 2/20 0.48
RECQL P46063 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
NPSR1 Q6W5P4 1/20 0.47
HDAC3 O15379 2/20 0.46
HDAC1 Q13547 2/20 0.46
HDAC10 Q969S8 2/20 0.46
HDAC6 Q9UBN7 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30497309 0.91 BRD4 (0.52) BRD4KDM4EALDH1A1HSD17B10TP53
SCHEMBL30497271 0.86 BRD4 (0.47) BRD4KDM4EALDH1A1HSD17B10TP53
SCHEMBL30899106 0.85 PTGER4 (0.48) KDM4EALDH1A1HSD17B10TSHRHTT
SCHEMBL29924458 0.85 PTGER4 (0.48) KDM4EALDH1A1HSD17B10TSHRHTT
SCHEMBL30497263 0.81 KCNH2 (0.55) KDM4EALDH1A1HSD17B10TSHRHTT
SCHEMBL3619365 0.78 MAPK1 (0.61) KDM4EALDH1A1HSD17B10HTTPOLB
SCHEMBL11145191 0.78 KDM4E (0.65) KDM4EALDH1A1HSD17B10
SCHEMBL4780057 0.77 CYP2C19 (0.60) KDM4EALDH1A1HSD17B10TSHRHTT
SCHEMBL5054186 0.76 POLB (0.57) BRD4KDM4EALDH1A1HSD17B10TP53
SCHEMBL1708203 0.75 HTT (0.60) BRD4KDM4EALDH1A1HSD17B10TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3481814-B1 TETRAHYDRONAPHTHYRIDINEPENTANAMIDE INTEGRIN ANTAGONISTS UNIV ROCKEFELLER (US) 2022-04-27 EP disclosed
US-11192889-B2 Tetrahydronaphthyridinepentanamide integrin antagonists THE ROCKEFELLER UNIVERSITY (US) 2021-12-07 US disclosed
US-20200181138-A1 TETRAHYDRONAPHTHYRIDINEPENTANAMIDE INTEGRIN ANTAGONISTS THE ROCKEFELLER UNIVERSITY (US) 2020-06-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200181138-A1 TETRAHYDRONAPHTHYRIDINEPENTANAMIDE INTEGRIN ANTAGONISTS ITGAV, ITGB3, ITGA4 BRD4 2320/4885KDM4E 3442/4885ALDH1A1 2465/4885
US-11192889-B2 Tetrahydronaphthyridinepentanamide integrin antagonists ITGAV, ITGB3, ITGA4 BRD4 2320/4885KDM4E 3442/4885ALDH1A1 2465/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.